
    
      This is an open-label, standard 3-3 dose finding scheme with a modification that allows
      intra-patient dose modification to determine maximum tolerated dose and toxicity profile of
      LBH589 in patients with recurrent or refractory Hodgkin's or non-Hodgkin's lymphoma.
    
  